Therapy-related leukemia has nearly tripled over 30 years as more cancer survivors live longer
As cancer treatments have improved and more patients survive their primary cancers, a concerning side effect has emerged: therapy-related acute myeloid leukemia (tAML), a severe leukemia caused by the DNA-damaging effects of chemotherapy and radiation used to treat other cancers.
Therapy-related leukemia has nearly tripled over 30 years as more cancer survivors live longer
As cancer treatments have improved and more patients survive their primary cancers, a concerning side effect has emerged: therapy-related acute myeloid leukemia (tAML), a severe leukemia caused by the DNA-damaging effects of chemotherapy and radiation used to treat other cancers.
A Japanese study found that tAML incidence increased almost threefold over the past 30 years, rising from 0.13 per 100,000 population to higher rates — a direct consequence of the expanding population of cancer survivors who have been exposed to genotoxic therapies. While this represents a success story in cancer survival, it creates a new cancer risk for long-term survivors.
These data have implications for surveillance strategies in cancer survivors and raise questions about whether newer, less genotoxic treatments could reduce tAML rates going forward.
Key Findings
- Therapy-related AML incidence increased approximately threefold over 30 years in Japan
- Rate rose from 0.13 per 100,000 population to higher levels (consistent with growing survivor population)
- Rising incidence directly tied to the expanding pool of cancer survivors who received genotoxic therapies
- Study data from Japan, one of few countries with comprehensive cancer registry data
- tAML represents a serious late effect of cancer treatment with poor prognosis
Implications
Oncologists should counsel patients about the long-term risk of tAML when recommending chemotherapy and radiation regimens, particularly in younger patients with long expected survival. Development of less genotoxic treatment alternatives and better surveillance protocols for tAML in survivors are clinical priorities.
Caveats
Based on Japanese population data; trends may differ in other countries with different treatment practices. News summary only; full methodology not available. Observational epidemiology cannot establish causation at the individual level. Summary based on abstract only.
Source: MedPage Hematology/Oncology — 2026-04-07
